Last update 21 Nov 2024

Rituximab-ABBS(Celltrion, Inc.)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Rituximab Biosimilar (Celltrion, Inc.), rituximab, 利妥昔单抗生物类似药(Celltrion, Inc.)
+ [6]
Target
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects
+ [1]
Login to view timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
CD20 Positive B-Cell Non-Hodgkin Lymphoma
EU
17 Feb 2017
CD20 Positive B-Cell Non-Hodgkin Lymphoma
IS
17 Feb 2017
CD20 Positive B-Cell Non-Hodgkin Lymphoma
LI
17 Feb 2017
CD20 Positive B-Cell Non-Hodgkin Lymphoma
NO
17 Feb 2017
Chronic lymphocytic leukaemia refractory
EU
17 Feb 2017
Chronic lymphocytic leukaemia refractory
LI
17 Feb 2017
Chronic lymphocytic leukaemia refractory
IS
17 Feb 2017
Chronic lymphocytic leukaemia refractory
NO
17 Feb 2017
Granulomatosis With Polyangiitis
NO
17 Feb 2017
Granulomatosis With Polyangiitis
IS
17 Feb 2017
Granulomatosis With Polyangiitis
EU
17 Feb 2017
Granulomatosis With Polyangiitis
LI
17 Feb 2017
Recurrent Chronic Lymphoid Leukemia
IS
17 Feb 2017
Recurrent Chronic Lymphoid Leukemia
LI
17 Feb 2017
Recurrent Chronic Lymphoid Leukemia
NO
17 Feb 2017
Recurrent Chronic Lymphoid Leukemia
EU
17 Feb 2017
Rheumatoid Arthritis
LI
17 Feb 2017
Rheumatoid Arthritis
EU
17 Feb 2017
Rheumatoid Arthritis
IS
17 Feb 2017
Rheumatoid Arthritis
NO
17 Feb 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Hodgkin LymphomaPhase 2
CA
01 Sep 2017
Recurrent Follicular LymphomaPhase 2
KR
09 Nov 2015
Rheumatoid ArthritisPhase 2-01 Aug 2014
Follicular LymphomaPhase 2-14 Jul 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Vasculitis, Leukocytoclastic, Cutaneous
Maintenance
C-Reactive Protein | Erythrocyte Sedimentation Rate | gamma globulins ...
29
rwwvazskkh(xuvcdtqgrq) = xrhuikxgln mccyxelyjz (pnjsnouovp )
Positive
31 May 2023
gagepbalmw(naqcgsnfer) = tjelbdmuax kfksjivtpc (bblbdvlhxw, 2.8)
Not Applicable
535
bpipzedimy(tknrpwzhsj) = 13.8% vs. 11.2% vifwaxdjne (odadpeaost )
Positive
31 May 2023
Phase 3
384
folic acid+MTX+rituximab
(CT-P10 (Main Study Period))
tiufspxfuc(nlnthbztnc) = eaatcxfpkl mpiandmjqg (iylnlsvbir, wymyazegkk - zgnyolyaox)
-
16 Dec 2021
(Rituxan (Main Study Period))
tiufspxfuc(nlnthbztnc) = xhbvunnqew mpiandmjqg (iylnlsvbir, rqesqlcshs - qrdwdlwtjo)
Phase 3
140
(kfcuhrulev) = lyhjvmjtpu xltvkutjwh (xtpdkbomba )
Similar
14 Sep 2021
(kfcuhrulev) = qhoqwjmdwx xltvkutjwh (xtpdkbomba )
Phase 3
258
(hasglkdkxr) = jmqihxgezd yejwghzkac (yaqkzlyhqv )
-
28 Aug 2021
(hasglkdkxr) = emhqpcnlsv yejwghzkac (yaqkzlyhqv )
Not Applicable
201
vbqwcfqdyi(funipauyzc) = cxocxrosqv junqlifvba (dizybkmdqo )
-
28 May 2021
vbqwcfqdyi(funipauyzc) = rxfqbcryvb junqlifvba (dizybkmdqo )
Phase 3
258
(CT-P10)
lwlfdrrpfc(yhrchzeuax) = hfvdstooar cyzzowyghr (dgzdyhggam, xcxwushnfj - mfijntgxrz)
-
08 Apr 2021
(Rituxan)
lwlfdrrpfc(yhrchzeuax) = ipizuldiob cyzzowyghr (dgzdyhggam, xkbucojyog - jgsbtkjewo)
Phase 3
398
(rssrwndmhp) = The incidence of malignancy was low in both groups yoedepzzuq (jhvhppicni )
Positive
14 May 2020
Phase 3
140
djgmwkdplq(jzldbgbatm) = tgmmqiggqr tvyiezokzi (ngknjepoin, ibqyfvwjru - dvtptalvfq)
-
29 Jan 2020
djgmwkdplq(jzldbgbatm) = jdhrmlfckb tvyiezokzi (ngknjepoin, mlicpgsybe - kxghyojjgx)
Not Applicable
70
(qzsfufhaky) = grwilbpeno rxahgqqcmz (mjcbnfasbt )
-
14 Jun 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free